29.04.2022 – 19:43

Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals

London (ots/PRNewswire)

Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any transaction with Opiant Pharmaceuticals, contrary to a PR Newswire announcement issued today indicating that Opiant Pharmaceuticals and Hikma have entered into a commercialisation and license agreement for OPNT003, Nasal Nalmefene, in Europe and the UK.

About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI: 549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/stable Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,700 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

Contact:

Hikma (Investors): Susan Ringdal,
EVP,
Strategic Planning and Global Affairs,
+44 (0)20 7399 2760/ +44 7776 477050; Guy Featherstone,
Senior Investor Relations Manager,
+44 (0)20 3892 4389/ +44 7795 896738; Layan Kalisse,
Investor Relations Analyst,
+44 (0)20 7399 2788/ +44 7970 709912; Teneo (Press),
Charles Armitstead,
Camilla Cunningham| + 44 (0) 7703 330269,
+ 44 (0) 7464 982426